ID   SCG1_RAT                Reviewed;         675 AA.
AC   O35314; A1A5N9; Q9QVG8; Q9QVH1;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   02-OCT-2024, entry version 139.
DE   RecName: Full=Secretogranin-1;
DE   AltName: Full=Chromogranin-B;
DE            Short=CgB;
DE   AltName: Full=Glucagonoma peptide;
DE   AltName: Full=Secretogranin-I;
DE            Short=SgI;
DE   Contains:
DE     RecName: Full=PE-11;
DE   Contains:
DE     RecName: Full=CCB peptide short form;
DE   Contains:
DE     RecName: Full=CCB peptide long form;
DE   Flags: Precursor;
GN   Name=Chgb;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=2641278; DOI=10.1007/bf02896890;
RA   Forss-Petter S., Danielson P., Battenberg E., Bloom F., Sutcliffe J.G.;
RT   "Nucleotide sequence and cellular distribution of rat chromogranin B
RT   (secretogranin I) mRNA in the neuroendocrine system.";
RL   J. Mol. Neurosci. 1:63-75(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Glucagonoma;
RX   PubMed=1954895; DOI=10.1210/endo-129-6-3147;
RA   Nielsen E., Welinder B.S., Madsen O.D.;
RT   "Chromogranin-B, a putative precursor of eight novel rat glucagonoma
RT   peptides through processing at mono-, di-, or tribasic residues.";
RL   Endocrinology 129:3147-3156(1991).
RN   [4]
RP   PROTEIN SEQUENCE OF 21-34; 85-93; 332-339 AND 345-353, AND SULFATION AT
RP   TYR-339.
RC   TISSUE=Pheochromocytoma;
RX   PubMed=3608978; DOI=10.1002/j.1460-2075.1987.tb02355.x;
RA   Benedum U.M., Lamouroux A., Konecki D.S., Hille A., Baeuerle P.A.,
RA   Frank R., Lottspeich F., Mallet J., Huttner W.B.;
RT   "The primary structure of human secretogranin I (chromogranin B):
RT   comparison with chromogranin A reveals homologous terminal domains and a
RT   large intervening variable region.";
RL   EMBO J. 6:1203-1211(1987).
RN   [5]
RP   AMIDATION AT ARG-674, SULFATION AT TYR-622, PHOSPHORYLATION AT SER-624,
RP   SYNTHESIS OF 615-674, AND MASS SPECTROMETRY.
RX   PubMed=18181560; DOI=10.1021/pr7006686;
RA   Taylor S.W., Sun C., Hsieh A., Andon N.L., Ghosh S.S.;
RT   "A sulfated, phosphorylated 7 kDa secreted peptide characterized by direct
RT   analysis of cell culture media.";
RL   J. Proteome Res. 7:795-802(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-93; SER-129; SER-147;
RP   SER-190; SER-255; SER-259; SER-333; SER-375; SER-490 AND SER-624, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Secretogranin-1 is a neuroendocrine secretory granule
CC       protein, which may be the precursor for other biologically active
CC       peptides.
CC   -!- SUBUNIT: Interacts with ITPR1 in the secretory granules.
CC       {ECO:0000250|UniProtKB:P23389}.
CC   -!- SUBCELLULAR LOCATION: Secreted. Note=Neuroendocrine and endocrine
CC       secretory granules. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, adrenal medulla and
CC       anterior pituitary. In the brain, localized to the hippocampal
CC       formation, the endocrine hypothalamus, the olfactory system, and in
CC       anatomically distinct structures in the pons-medulla.
CC       {ECO:0000269|PubMed:2641278}.
CC   -!- DEVELOPMENTAL STAGE: First expressed in the brain around embryonic days
CC       13-14, and peaks by postnatal day 20. {ECO:0000269|PubMed:2641278}.
CC   -!- PTM: Extensively processed in glucagonoma tissue by limited proteolysis
CC       at conserved basic residues. Alternative processing are seen in
CC       different tissues. The proglucagon-converting enzymes present in
CC       transformed alpha-cells are likely candidates to be involved in tissue-
CC       specific processing.
CC   -!- MASS SPECTROMETRY: [CCB peptide long form]: Mass=7270.2446;
CC       Method=MALDI; Note=Sulfated and phosphorylated CCB peptide long form.;
CC       Evidence={ECO:0000269|PubMed:18181560};
CC   -!- MASS SPECTROMETRY: [CCB peptide long form]: Mass=7190.3133;
CC       Method=MALDI; Note=Sulfated or phosphorylated CCB peptide long form.;
CC       Evidence={ECO:0000269|PubMed:18181560};
CC   -!- MASS SPECTROMETRY: [CCB peptide long form]: Mass=7110.2525;
CC       Method=MALDI; Note=CCB peptide long form without any modifications.;
CC       Evidence={ECO:0000269|PubMed:18181560};
CC   -!- MASS SPECTROMETRY: [CCB peptide short form]: Mass=7212.2845;
CC       Method=MALDI; Note=Sulfated and phosphorylated CCB peptide short form.;
CC       Evidence={ECO:0000269|PubMed:18181560};
CC   -!- MASS SPECTROMETRY: [CCB peptide short form]: Mass=7132.2800;
CC       Method=MALDI; Note=Sulfated or phosphorylated CCB peptide short form.;
CC       Evidence={ECO:0000269|PubMed:18181560};
CC   -!- MASS SPECTROMETRY: [CCB peptide short form]: Mass=7052.3410;
CC       Method=MALDI; Note=CCB peptide short form without any modifications.;
CC       Evidence={ECO:0000269|PubMed:18181560};
CC   -!- SIMILARITY: Belongs to the chromogranin/secretogranin protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF019974; AAB72089.1; -; mRNA.
DR   EMBL; BC128743; AAI28744.1; -; mRNA.
DR   PIR; D49164; D49164.
DR   RefSeq; NP_036658.2; NM_012526.2.
DR   AlphaFoldDB; O35314; -.
DR   SMR; O35314; -.
DR   IntAct; O35314; 2.
DR   MINT; O35314; -.
DR   STRING; 10116.ENSRNOP00000028892; -.
DR   GlyGen; O35314; 2 sites.
DR   iPTMnet; O35314; -.
DR   PhosphoSitePlus; O35314; -.
DR   jPOST; O35314; -.
DR   PaxDb; 10116-ENSRNOP00000028892; -.
DR   GeneID; 24259; -.
DR   KEGG; rno:24259; -.
DR   UCSC; RGD:2339; rat.
DR   AGR; RGD:2339; -.
DR   CTD; 1114; -.
DR   RGD; 2339; Chgb.
DR   VEuPathDB; HostDB:ENSRNOG00000021269; -.
DR   eggNOG; ENOG502QRBF; Eukaryota.
DR   HOGENOM; CLU_026095_0_0_1; -.
DR   InParanoid; O35314; -.
DR   OrthoDB; 5324197at2759; -.
DR   PhylomeDB; O35314; -.
DR   TreeFam; TF336596; -.
DR   Reactome; R-RNO-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-RNO-8957275; Post-translational protein phosphorylation.
DR   PRO; PR:O35314; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000021269; Expressed in cerebellum and 15 other cell types or tissues.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0030141; C:secretory granule; IDA:RGD.
DR   InterPro; IPR001819; Chromogranin_AB.
DR   InterPro; IPR018054; Chromogranin_CS.
DR   InterPro; IPR001990; Granin.
DR   PANTHER; PTHR10583; CHROMOGRANIN; 1.
DR   PANTHER; PTHR10583:SF4; SECRETOGRANIN-1; 1.
DR   Pfam; PF01271; Granin; 1.
DR   PRINTS; PR00659; CHROMOGRANIN.
DR   PROSITE; PS00422; GRANINS_1; 1.
DR   PROSITE; PS00423; GRANINS_2; 1.
PE   1: Evidence at protein level;
KW   Amidation; Cleavage on pair of basic residues; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Phosphoprotein; Proteoglycan;
KW   Reference proteome; Secreted; Signal; Sulfation.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000269|PubMed:3608978"
FT   CHAIN           21..675
FT                   /note="Secretogranin-1"
FT                   /id="PRO_0000005446"
FT   PEPTIDE         572..582
FT                   /note="PE-11"
FT                   /evidence="ECO:0000250|UniProtKB:P16014"
FT                   /id="PRO_0000432733"
FT   PEPTIDE         615..675
FT                   /note="CCB peptide long form"
FT                   /id="PRO_0000411990"
FT   PEPTIDE         615..674
FT                   /note="CCB peptide short form"
FT                   /id="PRO_0000005447"
FT   REGION          64..507
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          528..555
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          620..646
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        64..89
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        123..137
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        147..252
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        253..267
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        286..309
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        322..342
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        366..448
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        456..496
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         93
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         99
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         129
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         147
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         190
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         255
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         259
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         291
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         309
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05060"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         339
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:3608978"
FT   MOD_RES         362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05060"
FT   MOD_RES         372
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05060"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         469
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P23389"
FT   MOD_RES         490
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         540
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         563
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P23389"
FT   MOD_RES         622
FT                   /note="Sulfotyrosine; partial"
FT                   /evidence="ECO:0000269|PubMed:18181560"
FT   MOD_RES         624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18181560,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         674
FT                   /note="Arginine amide; in CCB peptide short form"
FT                   /evidence="ECO:0000269|PubMed:18181560"
FT   CARBOHYD        93
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000250|UniProtKB:P05060"
FT   CARBOHYD        236
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000250|UniProtKB:P05060"
FT   DISULFID        36..57
FT                   /evidence="ECO:0000250"
FT   CONFLICT        358
FT                   /note="Q -> R (in Ref. 1; AAB72089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        461..464
FT                   /note="EQEK -> GQGE (in Ref. 1; AAB72089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        588
FT                   /note="R -> K (in Ref. 1; AAB72089)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   675 AA;  77536 MW;  042B045B272074FC CRC64;
     MQRAMLLGLL GAAALAAVIS APVDNRDHNE EMVTRCIIEV LSNALSKSSA PTITPECRQV
     LRKSGKEVKG EEKGENENSK FEVRLLRDPS DASVGRWASS REETGAPVED SPGQAKVDNE
     EWTGGGGHSR EAVDDQESLH PSNQQVSKEA KIRHSEERGG KEEEEEEGKI YPKGEHRGDA
     GEEKKHTEES GEKHNAFSNK RSEASAKKKE ESVARAEAHF VELEKTHSRE QSSQESGEET
     RRQEKPQELP DQDQSEEESE EGEEGEEGAT SEVTKRRPRH HHWRSQSNKP SYEGRRPLSE
     ERKHAAGESK DANVATANLG EKRGHHLAHY RASEEEPDYG EELRSYPGFQ APQGLQYQGR
     GSEEVRAPSP RSEESQEKEY KRNHPDSELE STANRHSEET EEERSYEGAK GRQHRGRGRE
     PGAYPALDSR QEKRLLDEGH DPVHESPVDT AKRYPQSKWQ EQEKNYLNYD EEGDQGRWWQ
     QEEQLEPEES REEVSFPDRQ YAPYPTTEKR KRLGALFNPY FDPLQWKNSD FEKKGNPDDS
     FLDDDGEDGN GVTMTEKNFF PEYNYDWWEK RPFSEDVNWG YEKRSFARAP HLDLKRQYDD
     GVAELDQLLH YRKKAAEFPD FYDSEEQMGP HQEAEDEKDR ADQRVLTEEE KKELENLAAM
     DLELQKIAEK FSQRG
//
